Korean Daewoong Pharmaceutical Opens R&D Center in India
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's Daewoong Pharmaceutical opened a new research and development center Jan. 20 in the southern India city of Hyderabad as it tries to pave the way for the development of what it called "different generics" and new brand products for the U.S. and European markets
You may also be interested in...
Eurand Inks Deal With Daewoong To Market Muscle Relaxant in Korea
SHANGHAI - Eurand has signed a license and distribution agreement with Daewoong Pharmaceutical to launch extended-release muscle relaxantAmrix (cyclobenzaprine) in Korea, the Milan-based company announced Aug. 1
Beijing Attracts Billion-Yuan Investment For Health Care Projects
To accelerate the development of the biopharmaceutical industry, Beijing Municipal Bureau of Industrial Development is stepping up efforts to provide investors with policy consulting and tracking services. The city has this year signed up eight major health care investments totaling 3.83 billion yuan ($548 million). The projects comprise: (1) joint production of MMR (measles, mumps and rubella) vaccines by GSK and Xili Pharmaceutical Group; (2) Genzyme Biotech Beijing's R&D and laboratory production project; (3) Kaizheng Biotech's human blood substitutes and new drug R&D production base; (4) Xiuzheng Pharmaceutical Group's industrial park; (5) Korean Daewoong Pharmaceutical's R&D center and production base; (6) Tiandao Biotech's monoclonal antibody R&D and production base; (7) Mindray's Beijing academic institution; and (8) Genova Biotech's Novaferon production base. (Click here for more - Chinese language)
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).